21/03/2017
MINORYX THERAPEUTICS SUCCESSFULLY COMPLETES PHASE 1 CLINICAL TRIAL FOR LEAD CANDIDATE MIN-102
MIN-102 was well-tolerated at much higher doses than those required for efficacy. MIN-102 exhibited linear pharmacokinetics and no food effects were observed. Blood brain barrier penetration and biomarkers confirm PPAR gamma [...]
